Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-29T12:47:52.750Z Has data issue: false hasContentIssue false

Author response

Published online by Cambridge University Press:  02 January 2018

Fiona Martin
Affiliation:
University of Dundee Medical School, Ninewells Hospital, email: fiona.martin5@nhs.net
Tim Elworthy
Affiliation:
Medical School, Dundee, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2013

Martin & Elworthy report that the biggest reason for prescribing electroconvulsive therapy (ECT) less frequently than before is the perception among psychiatrists that ‘more effective medication’ now exists. Reference Cipriani, La Ferla, Furukawa, Signoretti, Nakagawa and Churchill1 Unfortunately, the authors collude with this exaggerated view, claiming that ‘psychiatric medications have undoubtedly become more effective over recent years’. Their bold statement references a 2002 story in The New York Times.

Meta-analysis shows that the current first-line treatments for depressive disorder, selective serotonin reuptake inhibitors, are marginally less effective than older tricyclic antidepressants (TCAs), while serotonin-noradrenaline reuptake inhibitors show no statistically significant advantage over TCAs.2 One newer drug, reboxetine, does not work at all,3 yet is inexplicably still licensed as an antidepressant.

Lithium remains the only true mood stabiliser: it is the only drug with efficacy in treating acute manic and depressive symptoms and in prophylaxis of manic and depressive symptoms in bipolar disorder.4

One has to conclude that the prevailing delusion that treatments across psychiatry have become more effective has been mediated by the pharmaceutical industry. Psychiatrists should take their evidence from meta-analyses in peer-reviewed journals, not from advertising representatives and certainly not from the newsstand.

References

1 Cipriani, A, La Ferla, T, Furukawa, TA, Signoretti, A, Nakagawa, A, Churchill, R, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; 2: CD006117 Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.